http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 18 Sep 2026 16:42:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioNTech+SE+++++++++++++++For%3A+Sep+17++Filed+by%3A+Sahin+Ugur/27081048.html si-local-file:///var/storage/secattach/20260918/27081048.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioNTech+SE+++++++++++++++For%3A+Sep+17++Filed+by%3A+Sahin+Ugur/27081048.html Fri, 18 Sep 2026 16:42:00 -0400 BNTX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BioNTech+SE+++++++++++++++For%3A+Sep+18/27080630.html si-local-file:///var/storage/secattach/20260918/27080630.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BioNTech+SE+++++++++++++++For%3A+Sep+18/27080630.html Fri, 18 Sep 2026 16:10:00 -0400 BNTX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioNTech+SE+++++++++++++++For%3A+Sep+15++Filed+by%3A+Sahin+Ugur/27070887.html si-local-file:///var/storage/secattach/20260916/27070887.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioNTech+SE+++++++++++++++For%3A+Sep+15++Filed+by%3A+Sahin+Ugur/27070887.html Wed, 16 Sep 2026 16:46:00 -0400 BNTX http://www.streetinsider.com/Analyst+Comments/UBS+Reiterates+Buy+Rating+on+BioNTech+%28BNTX%29+Following+Lung+Cancer+Updates/27067958.html <p>UBS analyst David Dai reiterated a Buy rating and $135.00 price target on BioNTech (NASDAQ: BNTX).</p><p>The analyst commented, "BNTX presented two important lung cancer updates at WCLC 2026 -- 1) first ever PD-L1xVEGF + B7-H3 ADC combo (pumi+Elfe-D) in 1L ES-SCLC, and 2) gotistobart (anti-CTLA) OS data in 2L+ NSCLC. Pumi+Elf-D exceeded our expectations with potentially best-in-class efficacy and clean safety in 1L ES SCLC, supporting advancement into Phase 3 trial. Combining a PD-L1×VEGF bispecific with an ADC showed 70% ORR overall and 92% ORR in 1L, exceeding that of pumi+chemo combo and other B7-H3 ADCs. Safety looked clean with no DLT and low discontinuation rate (3.9%). Moreover, http://www.streetinsider.com/Analyst+Comments/UBS+Reiterates+Buy+Rating+on+BioNTech+%28BNTX%29+Following+Lung+Cancer+Updates/27067958.html Wed, 16 Sep 2026 08:40:39 -0400 BNTX http://www.streetinsider.com/Analyst+PT+Change/BioNTech+%28BNTX%29+PT+Raised+to+%24140+at+Berenberg/27066735.html Berenberg analyst Harry Gillis raised the price target on BioNTech (NASDAQ: BNTX) to $140.00 (from $132.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/BioNTech+%28BNTX%29+PT+Raised+to+%24140+at+Berenberg/27066735.html Wed, 16 Sep 2026 04:57:55 -0400 BNTX http://www.streetinsider.com/Press+Releases/A+%2457+Billion+Antiviral+Market+Is+Taking+Shape+As+The+World+Prepares+For+The+Next+Viral+Threat/27062008.html <p><strong>A Growing Global Threat From Emerging Viruses Is Fueling Urgent Demand For New Treatments And Creating A Potentially Massive Market For Innovative Antiviral Developers</strong></p><p align="left">NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The antiviral market is entering a period where the need for new treatments is becoming impossible to ignore. Viral outbreaks can emerge quickly, cross borders and overwhelm healthcare systems before effective therapies are ready. That creates a large and growing commercial opportunity for companies working on drugs that can actually stop viral diseases rather than simply manage their symptoms. The http://www.streetinsider.com/Press+Releases/A+%2457+Billion+Antiviral+Market+Is+Taking+Shape+As+The+World+Prepares+For+The+Next+Viral+Threat/27062008.html Tue, 15 Sep 2026 09:00:00 -0400 BNTX GILD MRNA PFE http://www.streetinsider.com/Press+Releases/A+%2457+Billion+Antiviral+Market+Is+Taking+Shape+As+The+World+Prepares+For+The+Next+Viral+Threat/27062008.html <p><strong>A Growing Global Threat From Emerging Viruses Is Fueling Urgent Demand For New Treatments And Creating A Potentially Massive Market For Innovative Antiviral Developers</strong></p><p align="left">NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The antiviral market is entering a period where the need for new treatments is becoming impossible to ignore. Viral outbreaks can emerge quickly, cross borders and overwhelm healthcare systems before effective therapies are ready. That creates a large and growing commercial opportunity for companies working on drugs that can actually stop viral diseases rather than simply manage their symptoms. The http://www.streetinsider.com/Press+Releases/A+%2457+Billion+Antiviral+Market+Is+Taking+Shape+As+The+World+Prepares+For+The+Next+Viral+Threat/27062008.html Tue, 15 Sep 2026 09:00:00 -0400 BNTX GILD MRNA PFE http://www.streetinsider.com/Press+Releases/A+%2457+Billion+Antiviral+Market+Is+Taking+Shape+As+The+World+Prepares+For+The+Next+Viral+Threat/27062008.html <p><strong>A Growing Global Threat From Emerging Viruses Is Fueling Urgent Demand For New Treatments And Creating A Potentially Massive Market For Innovative Antiviral Developers</strong></p><p align="left">NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The antiviral market is entering a period where the need for new treatments is becoming impossible to ignore. Viral outbreaks can emerge quickly, cross borders and overwhelm healthcare systems before effective therapies are ready. That creates a large and growing commercial opportunity for companies working on drugs that can actually stop viral diseases rather than simply manage their symptoms. The http://www.streetinsider.com/Press+Releases/A+%2457+Billion+Antiviral+Market+Is+Taking+Shape+As+The+World+Prepares+For+The+Next+Viral+Threat/27062008.html Tue, 15 Sep 2026 09:00:00 -0400 BNTX GILD MRNA PFE http://www.streetinsider.com/Press+Releases/A+%2457+Billion+Antiviral+Market+Is+Taking+Shape+As+The+World+Prepares+For+The+Next+Viral+Threat/27062008.html <p><strong>A Growing Global Threat From Emerging Viruses Is Fueling Urgent Demand For New Treatments And Creating A Potentially Massive Market For Innovative Antiviral Developers</strong></p><p align="left">NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The antiviral market is entering a period where the need for new treatments is becoming impossible to ignore. Viral outbreaks can emerge quickly, cross borders and overwhelm healthcare systems before effective therapies are ready. That creates a large and growing commercial opportunity for companies working on drugs that can actually stop viral diseases rather than simply manage their symptoms. The http://www.streetinsider.com/Press+Releases/A+%2457+Billion+Antiviral+Market+Is+Taking+Shape+As+The+World+Prepares+For+The+Next+Viral+Threat/27062008.html Tue, 15 Sep 2026 09:00:00 -0400 BNTX GILD MRNA PFE http://www.streetinsider.com/Globe+Newswire/A+%2457+Billion+Antiviral+Market+Is+Taking+Shape+As+The+World+Prepares+For+The+Next+Viral+Threat/27062008.html <p><strong>A Growing Global Threat From Emerging Viruses Is Fueling Urgent Demand For New Treatments And Creating A Potentially Massive Market For Innovative Antiviral Developers</strong></p><p align="left">NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The antiviral market is entering a period where the need for new treatments is becoming impossible to ignore. Viral outbreaks can emerge quickly, cross borders and overwhelm healthcare systems before effective therapies are ready. That creates a large and growing commercial opportunity for companies working on drugs that can actually stop viral diseases rather than simply manage their symptoms. The http://www.streetinsider.com/Globe+Newswire/A+%2457+Billion+Antiviral+Market+Is+Taking+Shape+As+The+World+Prepares+For+The+Next+Viral+Threat/27062008.html Tue, 15 Sep 2026 09:00:00 -0400 BNTX GILD MRNA PFE http://www.streetinsider.com/Globe+Newswire/A+%2457+Billion+Antiviral+Market+Is+Taking+Shape+As+The+World+Prepares+For+The+Next+Viral+Threat/27062008.html <p><strong>A Growing Global Threat From Emerging Viruses Is Fueling Urgent Demand For New Treatments And Creating A Potentially Massive Market For Innovative Antiviral Developers</strong></p><p align="left">NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The antiviral market is entering a period where the need for new treatments is becoming impossible to ignore. Viral outbreaks can emerge quickly, cross borders and overwhelm healthcare systems before effective therapies are ready. That creates a large and growing commercial opportunity for companies working on drugs that can actually stop viral diseases rather than simply manage their symptoms. The http://www.streetinsider.com/Globe+Newswire/A+%2457+Billion+Antiviral+Market+Is+Taking+Shape+As+The+World+Prepares+For+The+Next+Viral+Threat/27062008.html Tue, 15 Sep 2026 09:00:00 -0400 BNTX GILD MRNA PFE http://www.streetinsider.com/Globe+Newswire/A+%2457+Billion+Antiviral+Market+Is+Taking+Shape+As+The+World+Prepares+For+The+Next+Viral+Threat/27062008.html <p><strong>A Growing Global Threat From Emerging Viruses Is Fueling Urgent Demand For New Treatments And Creating A Potentially Massive Market For Innovative Antiviral Developers</strong></p><p align="left">NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The antiviral market is entering a period where the need for new treatments is becoming impossible to ignore. Viral outbreaks can emerge quickly, cross borders and overwhelm healthcare systems before effective therapies are ready. That creates a large and growing commercial opportunity for companies working on drugs that can actually stop viral diseases rather than simply manage their symptoms. The http://www.streetinsider.com/Globe+Newswire/A+%2457+Billion+Antiviral+Market+Is+Taking+Shape+As+The+World+Prepares+For+The+Next+Viral+Threat/27062008.html Tue, 15 Sep 2026 09:00:00 -0400 BNTX GILD MRNA PFE http://www.streetinsider.com/Globe+Newswire/A+%2457+Billion+Antiviral+Market+Is+Taking+Shape+As+The+World+Prepares+For+The+Next+Viral+Threat/27062008.html <p><strong>A Growing Global Threat From Emerging Viruses Is Fueling Urgent Demand For New Treatments And Creating A Potentially Massive Market For Innovative Antiviral Developers</strong></p><p align="left">NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The antiviral market is entering a period where the need for new treatments is becoming impossible to ignore. Viral outbreaks can emerge quickly, cross borders and overwhelm healthcare systems before effective therapies are ready. That creates a large and growing commercial opportunity for companies working on drugs that can actually stop viral diseases rather than simply manage their symptoms. The http://www.streetinsider.com/Globe+Newswire/A+%2457+Billion+Antiviral+Market+Is+Taking+Shape+As+The+World+Prepares+For+The+Next+Viral+Threat/27062008.html Tue, 15 Sep 2026 09:00:00 -0400 BNTX GILD MRNA PFE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioNTech+SE+++++++++++++++For%3A+Sep+11++Filed+by%3A+Sahin+Ugur/27059073.html si-local-file:///var/storage/secattach/20260914/27059073.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioNTech+SE+++++++++++++++For%3A+Sep+11++Filed+by%3A+Sahin+Ugur/27059073.html Mon, 14 Sep 2026 16:51:00 -0400 BNTX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BioNTech+SE+++++++++++++++For%3A+Sep+14/27055844.html si-local-file:///var/storage/secattach/20260914/27055844.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BioNTech+SE+++++++++++++++For%3A+Sep+14/27055844.html Mon, 14 Sep 2026 08:29:00 -0400 BNTX http://www.streetinsider.com/Corporate+News/BioNTech+drug+shows+doubled+survival+in+lung+cancer+trial/27054605.html <p>BioNTech SE (Nasdaq: BNTX) and OncoC4, Inc. presented updated clinical trial data showing that their investigational drug gotistobart nearly doubled median overall survival compared with standard-of-care chemotherapy in previously treated patients with squamous non-small cell lung cancer (NSCLC).</p><p>The data, from stage 1 of the PRESERVE-003 Phase 3 clinical trial, showed a median overall survival of 18.5 months for patients treated with gotistobart versus 10.0 months for patients treated with docetaxel, a standard chemotherapy. The hazard ratio was 0.56, with a nominal p-value of 0.0295. The findings were presented at the International Association for the Study of Lung Cancer 2026 World http://www.streetinsider.com/Corporate+News/BioNTech+drug+shows+doubled+survival+in+lung+cancer+trial/27054605.html Mon, 14 Sep 2026 04:27:21 -0400 BNTX http://www.streetinsider.com/FDA/BioNTech+drug+shows+doubled+survival+in+lung+cancer+trial/27054605.html <p>BioNTech SE (Nasdaq: BNTX) and OncoC4, Inc. presented updated clinical trial data showing that their investigational drug gotistobart nearly doubled median overall survival compared with standard-of-care chemotherapy in previously treated patients with squamous non-small cell lung cancer (NSCLC).</p><p>The data, from stage 1 of the PRESERVE-003 Phase 3 clinical trial, showed a median overall survival of 18.5 months for patients treated with gotistobart versus 10.0 months for patients treated with docetaxel, a standard chemotherapy. The hazard ratio was 0.56, with a nominal p-value of 0.0295. The findings were presented at the International Association for the Study of Lung Cancer 2026 World http://www.streetinsider.com/FDA/BioNTech+drug+shows+doubled+survival+in+lung+cancer+trial/27054605.html Mon, 14 Sep 2026 04:27:21 -0400 BNTX http://www.streetinsider.com/Press+Releases/BioNTech+and+OncoC4+Present+Updated+Data+Showing+Gotistobart+Nearly+Doubled+Median+Overall+Survival+versus+Standard-of-Care+Chemotherapy+in+Previously+Treated+Squamous+Non-Small+Cell+Lung+Cancer+Patie/27054576.html <ul><li style="margin-top:0cm; margin-bottom:0cm; text-align:justify;"><i>Gotistobart continues to show potential as</i> <i>chemotherapy-free monotherapy to reignite anti-tumor immunity in previously treated patients with squamous non-small cell lung cancer, where median survival with current standard of care treatments is less than one year¹</i></li><li style="margin-top:0cm; margin-bottom:0cm; text-align:justify;"><i>Gotistobart demonstrated a median overall survival of 18.5 months compared to 10.0 months with standard-of-care chemotherapy in updated data from stage 1 of the PRESERVE-003 Phase 3 clinical trial, nearly doubling median survival in this patient population</i></li><li style="margin-top:0cm; margin-bottom:0cm; text-align:justify;"><i>Findings are consistent with gotistobart’s differentiated mechanism of action as an investigational immunomodulator that selectively enhances regulatory T cell depletion http://www.streetinsider.com/Press+Releases/BioNTech+and+OncoC4+Present+Updated+Data+Showing+Gotistobart+Nearly+Doubled+Median+Overall+Survival+versus+Standard-of-Care+Chemotherapy+in+Previously+Treated+Squamous+Non-Small+Cell+Lung+Cancer+Patie/27054576.html Mon, 14 Sep 2026 04:00:00 -0400 BNTX http://www.streetinsider.com/Globe+Newswire/BioNTech+and+OncoC4+Present+Updated+Data+Showing+Gotistobart+Nearly+Doubled+Median+Overall+Survival+versus+Standard-of-Care+Chemotherapy+in+Previously+Treated+Squamous+Non-Small+Cell+Lung+Cancer+Patie/27054576.html <ul><li style="margin-top:0cm; margin-bottom:0cm; text-align:justify;"><i>Gotistobart continues to show potential as</i> <i>chemotherapy-free monotherapy to reignite anti-tumor immunity in previously treated patients with squamous non-small cell lung cancer, where median survival with current standard of care treatments is less than one year¹</i></li><li style="margin-top:0cm; margin-bottom:0cm; text-align:justify;"><i>Gotistobart demonstrated a median overall survival of 18.5 months compared to 10.0 months with standard-of-care chemotherapy in updated data from stage 1 of the PRESERVE-003 Phase 3 clinical trial, nearly doubling median survival in this patient population</i></li><li style="margin-top:0cm; margin-bottom:0cm; text-align:justify;"><i>Findings are consistent with gotistobart’s differentiated mechanism of action as an investigational immunomodulator that selectively enhances regulatory T cell depletion http://www.streetinsider.com/Globe+Newswire/BioNTech+and+OncoC4+Present+Updated+Data+Showing+Gotistobart+Nearly+Doubled+Median+Overall+Survival+versus+Standard-of-Care+Chemotherapy+in+Previously+Treated+Squamous+Non-Small+Cell+Lung+Cancer+Patie/27054576.html Mon, 14 Sep 2026 04:00:00 -0400 BNTX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioNTech+SE+++++++++++++++For%3A+Sep+10++Filed+by%3A+Sahin+Ugur/27053696.html si-local-file:///var/storage/secattach/20260911/27053696.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioNTech+SE+++++++++++++++For%3A+Sep+10++Filed+by%3A+Sahin+Ugur/27053696.html Fri, 11 Sep 2026 17:18:00 -0400 BNTX http://www.streetinsider.com/General+News/BMO+lowers+Amgen%2C+BioNTech+to+Market+Perform+as+risk-reward+shifts/27033150.html <p>Investing.com -- BMO Capital Markets downgraded Amgen and BioNTech to Market Perform from Outperform on Tuesday, citing limited near-term upside and more balanced risk-reward for biopharma companies.</p><p>BMO analyst Evan Seigerman cut Amgen’s rating while maintaining a price target of $450. Seigerman said commercial execution is now the base case for the stock, with shares up 34% year-to-date, outperforming the broader S&P 500 and the NYSE Arca Pharmaceutical indexes. </p><p><span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Amgen</span></span> continues to face significant loss-of-exclusivity headwinds, Seigerman said, with pressure visible on Prolia/XGEVA, Enbrel, Otezla and Kyprolis. He said the company’s obesity drug MariTide "offers a potentially differentiated http://www.streetinsider.com/General+News/BMO+lowers+Amgen%2C+BioNTech+to+Market+Perform+as+risk-reward+shifts/27033150.html Tue, 08 Sep 2026 07:22:58 -0400 AMGN BNTX http://www.streetinsider.com/General+News/BMO+lowers+Amgen%2C+BioNTech+to+Market+Perform+as+risk-reward+shifts/27033150.html <p>Investing.com -- BMO Capital Markets downgraded Amgen and BioNTech to Market Perform from Outperform on Tuesday, citing limited near-term upside and more balanced risk-reward for biopharma companies.</p><p>BMO analyst Evan Seigerman cut Amgen’s rating while maintaining a price target of $450. Seigerman said commercial execution is now the base case for the stock, with shares up 34% year-to-date, outperforming the broader S&P 500 and the NYSE Arca Pharmaceutical indexes. </p><p><span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Amgen</span></span> continues to face significant loss-of-exclusivity headwinds, Seigerman said, with pressure visible on Prolia/XGEVA, Enbrel, Otezla and Kyprolis. He said the company’s obesity drug MariTide "offers a potentially differentiated http://www.streetinsider.com/General+News/BMO+lowers+Amgen%2C+BioNTech+to+Market+Perform+as+risk-reward+shifts/27033150.html Tue, 08 Sep 2026 07:22:58 -0400 AMGN BNTX http://www.streetinsider.com/Investing/BMO+lowers+Amgen%2C+BioNTech+to+Market+Perform+as+risk-reward+shifts/27033150.html <p>Investing.com -- BMO Capital Markets downgraded Amgen and BioNTech to Market Perform from Outperform on Tuesday, citing limited near-term upside and more balanced risk-reward for biopharma companies.</p><p>BMO analyst Evan Seigerman cut Amgen’s rating while maintaining a price target of $450. Seigerman said commercial execution is now the base case for the stock, with shares up 34% year-to-date, outperforming the broader S&P 500 and the NYSE Arca Pharmaceutical indexes. </p><p><span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Amgen</span></span> continues to face significant loss-of-exclusivity headwinds, Seigerman said, with pressure visible on Prolia/XGEVA, Enbrel, Otezla and Kyprolis. He said the company’s obesity drug MariTide "offers a potentially differentiated http://www.streetinsider.com/Investing/BMO+lowers+Amgen%2C+BioNTech+to+Market+Perform+as+risk-reward+shifts/27033150.html Tue, 08 Sep 2026 07:22:58 -0400 AMGN BNTX http://www.streetinsider.com/Investing/BMO+lowers+Amgen%2C+BioNTech+to+Market+Perform+as+risk-reward+shifts/27033150.html <p>Investing.com -- BMO Capital Markets downgraded Amgen and BioNTech to Market Perform from Outperform on Tuesday, citing limited near-term upside and more balanced risk-reward for biopharma companies.</p><p>BMO analyst Evan Seigerman cut Amgen’s rating while maintaining a price target of $450. Seigerman said commercial execution is now the base case for the stock, with shares up 34% year-to-date, outperforming the broader S&P 500 and the NYSE Arca Pharmaceutical indexes. </p><p><span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Amgen</span></span> continues to face significant loss-of-exclusivity headwinds, Seigerman said, with pressure visible on Prolia/XGEVA, Enbrel, Otezla and Kyprolis. He said the company’s obesity drug MariTide "offers a potentially differentiated http://www.streetinsider.com/Investing/BMO+lowers+Amgen%2C+BioNTech+to+Market+Perform+as+risk-reward+shifts/27033150.html Tue, 08 Sep 2026 07:22:58 -0400 AMGN BNTX http://www.streetinsider.com/Downgrades/BMO+Capital+Downgrades+BioNTech+%28BNTX%29+to+Market+Perform/27032270.html <p>BMO Capital analyst Evan David Seigerman downgraded BioNTech (NASDAQ: BNTX) from Outperform to Market Perform with a price target of $105.00 (from $128.00).</p><p>The analyst comments: “We downgrade shares of BNTX to Market Perform and reduce our target to $105 following a year in which BioNTech's biggest share moves came from other companies' data. Management has built a credible late-stage oncology franchise, and >€16B in cash (~$75/share) underwrites the downside. However, over the next twelve months we struggle to see greater upside without clear differentiation of pumitamig or the company's in development iNeST/FixVac programs.</p><p>Revenue guidance has been cut repeatedly, most recently http://www.streetinsider.com/Downgrades/BMO+Capital+Downgrades+BioNTech+%28BNTX%29+to+Market+Perform/27032270.html Tue, 08 Sep 2026 04:36:04 -0400 BNTX